Hanmi Pharm Wins KRW52.7 Billion Supply Deal for Three Cardiovascular and Respiratory Products

MT Newswires Live

05/21

Hanmi Pharm (KRX:128940) secured a supply agreement for three cardiovascular and respiratory products from New Jersey-based Organon International, according to a Thursday filing with the Korea Exchange.

The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.

Shares of Hanmi Pharm added more than 5% in recent trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2637384517"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637384517\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637384517?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637384517","market":"sh","top_or_hot":-1,"title":"Hanmi Pharm Wins KRW52.7 Billion Supply Deal for Three Cardiovascular and Respiratory Products","media":"MT Newswires Live","content":"<html><body><p> Hanmi Pharm (KRX:128940) secured a supply agreement for three cardiovascular and respiratory products from <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>-based Organon International, according to a Thursday filing with the Korea Exchange.</p><p>The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.</p><p>Shares of Hanmi Pharm added more than 5% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanmi Pharm Wins KRW52.7 Billion Supply Deal for Three Cardiovascular and Respiratory Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanmi Pharm Wins KRW52.7 Billion Supply Deal for Three Cardiovascular and Respiratory Products\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-21 18:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Hanmi Pharm (KRX:128940) secured a supply agreement for three cardiovascular and respiratory products from <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>-based Organon International, according to a Thursday filing with the Korea Exchange.</p><p>The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.</p><p>Shares of Hanmi Pharm added more than 5% in recent trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSII","symbol_name":"Cardiovascular Systems","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637384517","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637384517","pubTimestamp":1779357854,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hanmi Pharm  secured a supply agreement for three cardiovascular and respiratory products from New Jersey-based Organon International, according to a Thursday filing with the Korea Exchange.The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.Shares of Hanmi Pharm added more than 5% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSII":"Cardiovascular Systems","BK4082":"医疗保健设备","HAFC":"韩美金融","BK4211":"区域性银行"},"translate_title":"Hanmi Pharm赢得价值527亿韩元的三种心血管和呼吸产品供应协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSII":1.5,"HAFC":1.5},"content_text":"Hanmi Pharm (KRX:128940) secured a supply agreement for three cardiovascular and respiratory products from New Jersey-based Organon International, according to a Thursday filing with the Korea Exchange.The deal, valued at 52.7 billion won, is valid till May 17, 2036. The products will be supplied to the Philippines and Malaysia.Shares of Hanmi Pharm added more than 5% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}